<?xml version="1.0" encoding="UTF-8"?>
<ref id="cas14841-bib-0006">
 <label>6</label>
 <mixed-citation publication-type="journal" id="cas14841-cit-0006">
  <string-name>
   <surname>Yamada</surname>
   <given-names>Y</given-names>
  </string-name>, 
  <string-name>
   <surname>Denda</surname>
   <given-names>T</given-names>
  </string-name>, 
  <string-name>
   <surname>Gamoh</surname>
   <given-names>M</given-names>
  </string-name>, et al. 
  <article-title>S‐1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first‐line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open‐label, phase III, noninferiority trial</article-title>. 
  <source xml:lang="en">Ann Oncol</source>. 
  <year>2018</year>;
  <volume>29</volume>(
  <issue>3</issue>):
  <fpage>624</fpage>‐
  <lpage>631</lpage>.
  <pub-id pub-id-type="pmid">29293874</pub-id>
 </mixed-citation>
</ref>
